Todd C. Davis
Chief Executive Officer at Ligand Pharmaceuticals Incorporated
Sits on 3 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: Ligand Pharmaceuticals Incorporated, 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Palvella Therapeutics Inc. June 10, 202681.8%
-
Ligand Pharmaceuticals Incorporated June 5, 202698.2%
-
Pelthos Therapeutics Inc. December 17, 202599.9%
-
Ligand Pharmaceuticals Incorporated June 9, 202597.5%
-
Pelthos Therapeutics Inc. October 22, 2024100.0%
-
Ligand Pharmaceuticals Incorporated June 14, 202498.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | Ligand Pharmaceuticals Incorporated | Other | +132 | $160.71 | $21,214 |
| Jun 11, 2026 | Pelthos Therapeutics Inc. | Open-market purchase | +35,445 | $27.80 | $985,371 |
| Jun 11, 2026 | Pelthos Therapeutics Inc. | Open-market purchase | +503 | $28.73 | $14,451 |
| Mar 2, 2026 | Ligand Pharmaceuticals Incorporated | Grant or award | +10,495 | — | — |
| Feb 15, 2026 | Ligand Pharmaceuticals Incorporated | Shares withheld for tax | −2,039 | $183.83 | $374,829 |
| Feb 15, 2026 | Ligand Pharmaceuticals Incorporated | Shares withheld for tax | −4,255 | $183.83 | $782,197 |
| Feb 15, 2026 | Ligand Pharmaceuticals Incorporated | Shares withheld for tax | −2,805 | $183.83 | $515,643 |
| Feb 14, 2026 | Ligand Pharmaceuticals Incorporated | Grant or award | +20,782 | — | — |
| Feb 14, 2026 | Ligand Pharmaceuticals Incorporated | Shares withheld for tax | −8,178 | $183.83 | $1,503,362 |
| Feb 14, 2026 | Ligand Pharmaceuticals Incorporated | Grant or award | +39,644 | — | — |
| Feb 14, 2026 | Ligand Pharmaceuticals Incorporated | Shares withheld for tax | −15,600 | $183.83 | $2,867,748 |
| Dec 4, 2025 | Ligand Pharmaceuticals Incorporated | Gift | −130 | — | — |
| Jul 1, 2025 | Pelthos Therapeutics Inc. | Derivative conversion | +1,500,000 | $10.00 | $15,000,000 |
| Jun 30, 2025 | Ligand Pharmaceuticals Incorporated | Other | +233 | $91.08 | $21,222 |
| May 9, 2025 | Ligand Pharmaceuticals Incorporated | Open-market purchase | +1,680 | $104.57 | $175,678 |
Questions about Todd C. Davis
What boards is Todd C. Davis on?
Todd C. Davis sits on the boards of Ligand Pharmaceuticals Incorporated, Palvella Therapeutics Inc. and Pelthos Therapeutics Inc.
What company is Todd C. Davis the CEO of?
Todd C. Davis is Chief Executive Officer of Ligand Pharmaceuticals Incorporated.
How long has Todd C. Davis served on boards?
Our records show at least 8 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.